Fluicell CEO Newsletter 03, 2023

“I see great potential in our technology, and I think we have only scratched the surface of what it can achieve. I look forward to working for a broad acceptance of our technology in the pharmaceutical industry in order to expand our pipeline with new therapeutic areas and collaborations, with the goal of ultimately being able to make a big difference for patients with severe disease.”

These are the words of Carolina Trkulja, Fluicell’s new CEO. We spoke to Carolina to learn more about what drives her and what she brings to a Fluicell focused on providing world-class tissue products for drug screening and regenerative medicine. 

Read about Carolina Trkulja and her thoughts on Fluicell’s path forward in the new edition of our CEO newsletter, which you can access in both English and Swedish. You can also read the newsletter directly on our website.

Make sure to take the opportunity to listen to Carolina talk about the new strategic direction for Fluicell on November 2, 10-10:30. Connect to the livestream here: https://www.finwire.tv/webcast/fluicell/investerarpresentation